Achillion a good candidate for collaboration or takeover based on hepatitis C candidate, says Edison
US-based Achillion Pharmaceuticals (Nasdaq: ACHN) is in a prime position to develop its own all-oral hepatitis C treatment as it is the only standalone biotech company with drug candidates in three key classes for the indication, says Edison Equity Research, which has valued the company at $1.42 billion, or $14.5 per basic share.
The firm's all-oral, once-a-day, interferon- and ribavirin-free single pill hepatitis C treatment could be as competitive as current market leader, US biotech major Gilead Sciences’ (Nasdaq: GILD) SOF/LDV fixed-dose co-formulation.
Achillion’s offering is showing promising efficacy in early stages of development, and additional efficacy and safety data in more patients from later stage clinical trials will add value to the pipeline, and Edison believes this could lead to a possible corporate partnership deal.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze